Imagene AI is a technology company.
Imagene AI has raised $45.0M across 3 funding rounds.
Imagene AI has raised $45.0M in total across 3 funding rounds.
Imagene AI is a technology company specializing in multimodal foundation models for precision medicine, particularly in oncology. It develops a transformative SaaS platform called the OI Suite, powered by its proprietary Cross-Modality Intelligence Engine and the CanvOI Oncology Intelligence Foundation Model (developed with Oracle), which integrates imaging, molecular, omics data, and clinical records to enable biomarker discovery, patient identification, mechanism of action exploration, and trial optimization.[1][2][3] The platform serves biopharma companies, clinical institutions, and life sciences organizations, solving key challenges in precision oncology by uncovering complex patterns in biopsy images and limited-data environments, accelerating diagnostics, drug development, and personalized treatments without requiring deep machine learning expertise.[1][2] Recognized among the Top 25 Healthcare AI Companies of 2025 by The Healthcare Technology Report, Imagene demonstrates strong growth momentum through scalable AI tools that streamline workflows and enhance therapeutic success.[2]
Imagene AI emerged as a pioneer in AI-driven precision medicine, focusing on oncology through its multimodal foundation models and end-to-end OI Suite.[1][3][4] While specific founding details like the exact year or founders' names are not detailed in available sources, the company's backstory centers on building a "living & adaptive intelligence engine" that continuously learns from diverse data modalities to democratize precision medicine.[1][3] Early traction likely stemmed from collaborations, such as the CanvOI model with Oracle, and assembly of a world-class Medical Advisory Board featuring experts like David Agus (Founding CEO, Ellison Medical Institute), Natasha Leighl (Princess Margaret Cancer Centre), and Tony Mok (Chinese University of Hong Kong), signaling pivotal validation in translational research and clinical oncology.[1] This expert backing humanizes Imagene's mission, positioning it as a bridge between cutting-edge AI and real-world healthcare needs.[1][2]
Imagene stands out in the crowded healthcare AI space through these key strengths:
These features drive efficiency, accessibility, and predictive power in precision medicine.[2][3]
Imagene rides the wave of AI in precision oncology, where multimodal foundation models address the explosion of multi-omics and imaging data to enable proactive, personalized healthcare.[2] Timing is ideal amid surging demand for faster clinical trials and biomarker insights, fueled by market forces like rising cancer prevalence, regulatory pushes for precision therapies, and AI's ability to handle massive datasets responsibly.[1][2] By democratizing advanced tools via its OI Suite, Imagene influences the ecosystem, empowering non-experts in biopharma and clinics to scale initiatives, reduce trial failures, and expand therapeutic access—shifting oncology from reactive to predictive models.[2][3] Its 2025 Top 25 recognition underscores its role in transforming diagnostics and research, amplifying AI's impact on global patient outcomes.[2]
Imagene AI is poised for expansion as oncology AI demand grows, with the OI Suite likely evolving to incorporate more real-time data streams and broader therapeutic areas beyond cancer.[2] Trends like federated learning for privacy-preserving multi-institution datasets and deeper large language model integration will shape its trajectory, enhancing its "living intelligence" edge.[1] Influence may grow through partnerships (e.g., expanding Oracle collaborations) and advisory-driven innovations, solidifying its leadership in precision medicine. As a pioneer turning complex data into actionable insights, Imagene exemplifies how AI unlocks translational breakthroughs, optimizing trials and therapies in an era of data-driven healthcare.[1][2]
Imagene AI has raised $45.0M in total across 3 funding rounds.
Imagene AI's investors include Blumberg Capital, Oracle, Webtalk Ltd, Insight Partners, StageOne Ventures, Anne Wojcicki, Neil Hunt, Entrée Capital Ventures, Innovation Endeavors, M12.
Imagene AI has raised $45.0M across 3 funding rounds. Most recently, it raised $23.0M Series B in June 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2025 | $23.0M Series B | Blumberg Capital, Oracle, Webtalk Ltd | |
| May 1, 2022 | $19.0M Series A | Blumberg Capital, Insight Partners, Oracle, StageOne Ventures, Webtalk Ltd, Anne Wojcicki, Neil Hunt | |
| May 1, 2022 | $3.0M Seed | Blumberg Capital, Entrée Capital Ventures, Innovation Endeavors, M12 |